RAF1 and breast cancer: It has been reported that IL-17A treatment induces the activation of the MAPK/ERK pathway through the phosphorylation of c-RAF, P42/P44 MAPK, MEK and ERK in human nasal endothelial cells52, HUVECs53, macrophages54, and breast cancer cells55.